Explore Stanford technologies available for licensing:

HIV-1 infection destroys CD4+ T cells and can lead to acquired immunodeficiency syndrome (AIDS).

Researchers at Stanford have identified amino acid modifications in the IgG Fc region which extend its therapeutic half-life and improve its in vivo receptor binding.

Researchers at Stanford have developed fusion proteins, containing ACE2 domain linked to a fragment of non-neutralizing anti-SARS-CoV-2 spike protein antibody, with a greater breadth of protection than previously described similar fusion proteins.

Researchers at Stanford University have developed novel universal vaccine candidates for H5 influenza viruses.

Researchers at Stanford have invented a method using directed evolution for predicting antibody improved antibody variants.

Technology Reference
CZ Biohub SF ref. no. CZB-231S
Stanford ref. no. S21-400

Researchers at Stanford have developed a new microparticle vaccine scaffold for the development of immunogenic subunit vaccines.

Technology Reference
CZB-213S
Stanford ref. no. S21-152

Researchers at CZ Biohub SF and Stanford have developed unique fusion proteins that have broad therapeutic benefits for the treatment of infection by existing and future coronaviruses.

Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed PMD (Protect, Modify, Deprotect), an immunofocusing strategy that can be used in vaccine development for the generation of antibodies targeting a specific epitope.

Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have generated a crystal structure for human PD-1 in complex with one of its ligands, PD-L2, for use in small molecule inhibitor design.